Debashree Tosh-Mitchell, MD
Pulmonary Disease · North Kansas City, MONPI 1548433535
Payments from drug & device makers
Across 293 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$699
- Boehringer Ingelheim$401
- Regeneron Healthcare Solutions, Inc.$299
- Grifols USA, LLC$281
- Mylan Specialty L.p.$249
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,407100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,055 |
| GSK | 41 | $699 |
| Boehringer Ingelheim | 20 | $401 |
| Regeneron Healthcare Solutions, Inc. | 10 | $299 |
| Grifols USA, LLC | 13 | $281 |
| Mylan Specialty L.p. | 14 | $249 |
| Genentech USA, Inc. | 16 | $225 |
| Jazz Pharmaceuticals Inc. | 12 | $224 |
| AbbVie(2 entities) | 11 | $221 |
| Merck | 11 | $195 |
| Sunovion Pharmaceuticals Inc. | 18 | $187 |
| Electromed, Inc. | 10 | $164 |
| Novocure Inc. | 1 | $131 |
| Insmed, Inc. | 7 | $120 |
| Sanofi | 5 | $95 |
| United Therapeutics Corporation | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $80 |
| Advanced Respiratory, Inc | 4 | $72 |
| Actelion Pharmaceuticals US, Inc. | 3 | $64 |
| Harmony Biosciences LLC | 3 | $60 |
| Philips North America LLC | 3 | $59 |
| Amgen | 3 | $58 |
| Novartis | 3 | $52 |
| Pfizer | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Optinose US, Inc. | 1 | $28 |
| Resmed Corp | 1 | $26 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Circassia Inc. | 2 | $24 |
| Shire North American Group Inc | 2 | $22 |
| Baxter Healthcare | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Veran Medical Technologies, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,418 in reported general payments places this provider in the 60th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $268,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $130,000 |
| NucalaMepolizumab | 23 | $88,989 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $84,138 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $55,033 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $50,673 |
| Spiriva RespimatTiotropium Bromide | 53 | $49,072 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $37,927 |
| Arnuity ElliptaFluticasone Furoate | 91 | $30,039 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $16,476 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $16,270 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 108 | $14,561 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $13,241 |
| Spiriva HandihalerTiotropium Bromide | 13 | $11,671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 491 | $11,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $401 | $388,480168 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $699 | $350,869439 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,055 | $100,613179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in North Kansas City
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.